Loxapine for Reversal of Antipsychotic-Induced Metabolic Disturbances: A Chart Review

详细信息    查看全文

• 作者：Seema Jain ; Rebecca Andridge…
• 关键词：Loxapine ; Metabolic side effects ; Autism spectrum disorder ; Atypical antipsychotics
• 刊名：Journal of Autism and Developmental Disorders
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：46
• 期：4
• 页码：1344-1353
• 全文大小：432 KB
• 参考文献：Alvarez-Jimenez, M., Hetrick, S. E., Gonzalez-Blanch, C., Gleeson, J. F., & McGorry, P. D. (2008). Non-pharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomized controlled trials. British Journal of Psychiatry, 193, 101–107.CrossRef PubMed
  Aman, M. G., & Singh, N. N. (1986). Aberrant behavior checklist: Manual. East Aurora, NY: Slosson Educational Publications.
  American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorder, Fourth Edition revised. Arlington, VA: American Psychiatric Association.CrossRef
  Beherec, L., Lambrey, S., Quilici, G., Rosier, A., Falissard, B., & Guillin, O. (2011). Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors. Journal of Clinical Psychopharmacology, 31(3), 341–344.CrossRef PubMed
  Bobo, W. V., Cooper, W. O., Stein, C. M., Olfson, M., Graham, D., Daugherty, J., et al. (2013). Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry, 70(100), 1067–1075.CrossRef PubMed
  Brennand, K. J., Simone, A., Jou, J., Gelboin-Burkhart, C., Tran, N., Sangar, S., et al. (2011). Modelling schizophrenia using human induced pluripotent stem cells. Nature, 473(7346), 221–225.CrossRef PubMed PubMedCentral
  Brooks, J. O., Chang, H. S., & Krasnykh, O. (2009). Metabolic risks in older adults receiving second-generation antipsychotic medication. Current Psychiatry Reports, 11, 33.CrossRef PubMed
  Campbell, M., Anderson, L. T., Meier, M., Cohen, I. L., Small, A. M., Samit, C., et al. (1978). A comparison of haloperidol and behavior therapy and their interaction in autistic children. Journal of the American Academy of Child Psychiatry, 17(4), 640–655.CrossRef PubMed
  Correll, C. U., Robinson, D., Schooler, N., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., et al. (2014). Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: Baseline results from RAISE-ETP study. JAMA Psychiatry, 71(12), 1350–1363.CrossRef PubMed
  Doss, F. W. (1979). The effect of antipsychotic drugs on body weight: A retrospective review. Journal of Clinical Pyschiatry, 40, 528.
  Goudie, A. J., Cooper, G. D., & Halford, J. C. G. (2005). Antipsychotic-induced weight gain. Diabetes, Obesity and Metabolism, 7(5), 478–487.CrossRef PubMed
  Guy, W. (1976). Clinical Global Impression scale (CGI). The ECDEU Assessment Manual for Psychopharmacology-Revised, 76(338), 218–222.
  Hellings, J. A., Jadhav, M., Jain, S., Jadhav, S., & Genovese, A. (2015a). Low dose loxapine: neuromotor side effects and tolerability in autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology, 25(8), 618–624.CrossRef PubMed
  Hellings, J. A., Reed, G., Cain, S. E., Zhou, X., Barth, F. X., Aman, M. G., et al. (2015b). Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability. Journal of Child and Adolescent Psychopharmacology, 25(2), 150–159.CrossRef PubMed PubMedCentral
  Hellings, J. A., Zarcone, J. R., Crandall, K. C., Wallace, D., & Schroeder, S. R. (2001). Weight gain in a controlled study of risperidone in children, adolescents, and adults with mental retardation and autism. Journal of Child and Adolescent Psychopharmacology, 11, 229–238.CrossRef PubMed
  Jibson, M. D. (2014). First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects. In R. Herman (Ed.), UptoDate Waltham, MA. (Accessed June 17, 2014).
  Li, Z., Ichikawa, J., & Meltzer, H. Y. (2003). A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl), 167(3), 315–323.
  Lieberman, J. A., & Stroup, T. S. (2011). The NIMH-CATIE Schizophrenia Study: What did we learn? American Journal of Psychiatry, 168(8), 770–775.CrossRef PubMed
  Lynch, T., & Price, A. (2007). The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. American Family Physician, 76(3), 391–396.PubMed
  Mizuno, Y., Suzuki, T., Nakagawa, A., Yoshida, K., Mimura, M., Fleischhacker, W. W., et al. (2014). Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: A systematic review and meta-analysis. Schizophrenia Bulletin, 40(6), 1385–1403.CrossRef PubMed PubMedCentral
  Munetz, M. R., & Benjamin, S. (1988). How to examine patients using the Abnormal Involuntary Movement Scale. Psychiatric Services, 39(11), 1172–1177.CrossRef
  Newcomer, J., & Haupt, D. (2006). The metabolic effects of antipsychotic medications. Canadian Journal of Psychiatry, 51, 480–491.PubMed
  Pramyothin, P., & Khaodhiar, L. (2010). Metabolic syndrome with the atypical antipsychotics. Current opinion in Endocrinology, Diabetes, and Obesity, 17(5), 460–466.CrossRef PubMed
  Reinblatt, S. P., Abanilla, P. K., Jummani, R., & Coffey, B. (2006). Loxapine treatment in an Autistic child with aggressive behavior: Therapeutic challenges. Journal of Child and Adolescent Psychopharmacology, 16(5), 639–643.CrossRef PubMed
  Stahl, S.M. (2002). Essential psychopharmacology of antipsychotics and mood stabilizers. Cambridge: Cambridge University Press.
  Stahl, S. M. (2007). Essential psychopharmacology: The prescriber’s guide. New Delhi: Cambridge University Press.
  Wetterling, T., & MuBigbrodt, H. E. (1999). Weight gain: Side effect of atypical neuroleptics? Journal of Clinical Psychopharmacology, 19(4), 316–321.CrossRef PubMed
  Wu, R. R., Zhao, J. P., Jin, H., Shao, P., Fang, M. S., Guo, X. F., et al. (2008). Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain. JAMA, 299, 185–193.PubMed
  
• 作者单位：Seema Jain (1)
  Rebecca Andridge (2)
  Jessica A. Hellings (3)
  
  1. The Ohio State University College of Medicine, 370 W 9th Ave, Columbus, OH, 43210, USA
  2. The Ohio State University College of Public Health, Columbus, OH, USA
  3. The Ohio State University Nisonger Center, Columbus, OH, USA
  
• 刊物类别：Behavioral Science
• 刊物主题：Psychology
  Child and School Psychology
  Pediatrics
  
• 出版者：Springer Netherlands
• ISSN：1573-3432

文摘

Loxapine substitution is a promising option for patients with autism spectrum disorder (ASD) who develop antipsychotic-induced metabolic illness. We performed a chart review of 15 adolescents and adults meeting DSM-IV-TR criteria for ASD, all with antipsychotic-associated weight gain, who received low dose loxapine in an attempt to taper or discontinue the weight gain-associated antipsychotic. Mean weight loss was −5.7 kg, mean BMI reduction was −1.9, and mean triglyceride reduction was −33.7 mg/dl. At chart review, 14 of 15 subjects were rated 2 (Much Improved) or 1 (Very Much Improved) on the Clinical Global Impressions-Improvement scale (CGI-I). Low dose loxapine addition in most cases enabled taper of offending antipsychotics, significantly reversed drug-induced metabolic disturbances and improved irritability.